Structure and function of cytochromes P450 2B: From mechanism-based inactivators to X-ray crystal structures and back

Drug Metabolism and Disposition

Volumn 39, Issue 7, 2011, Pages 1113-1121

  Halpert, James R ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (4 CHLOROPHENYL)IMIDAZOLE; 1 BIPHENYL 4 METHYL 1H IMIDAZOLE; 4 (4 CHLOROPHENYL)IMIDAZOLE; BIFONAZOLE; CHLORAMPHENICOL; CHLORAMPHENICOL DERIVATIVE; CLOPIDOGREL; CYTOCHROME P450 2B; CYTOCHROME P450 2B1; CYTOCHROME P450 2B4; CYTOCHROME P450 2B6; DRUG METABOLITE; IMIDAZOLE DERIVATIVE; TICLOPIDINE; UNCLASSIFIED DRUG;

ACCURACY; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; DEUTERIUM EXCHANGE MASS SPECTROMETRY; DIMERIZATION; DRUG DESIGN; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME CONFORMATION; ENZYME ENGINEERING; ENZYME INACTIVATION; ENZYME INHIBITION; ENZYME INHIBITOR COMPLEX; ENZYME MECHANISM; ENZYME SPECIFICITY; ENZYME STRUCTURE; HETEROLOGOUS EXPRESSION; HUMAN; ISOTHERMAL TITRATION CALORIMETRY; LIGAND BINDING; MASS SPECTROMETRY; MOLECULAR CLONING; MOLECULAR DYNAMICS; MOLECULAR MODEL; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SEQUENCE HOMOLOGY; SITE DIRECTED MUTAGENESIS; THERMODYNAMICS; X RAY ANALYSIS; X RAY CRYSTALLOGRAPHY;

CATALYTIC DOMAIN; CLONING, MOLECULAR; CRYSTALLOGRAPHY, X-RAY; CYTOCHROME P-450 ENZYME SYSTEM; DNA, COMPLEMENTARY; LIGANDS; MODELS, MOLECULAR; PROTEIN CONFORMATION; STRUCTURE-ACTIVITY RELATIONSHIP;

BACTERIA (MICROORGANISMS); HARNESS; MAMMALIA; ORYCTOLAGUS CUNICULUS;

EID: 79959385330     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.111.039719     Document Type: Review

References (74)

1. Blobaum AL, Harris DL, and Hollenberg PF (2005) P450 active site architecture and reversibility: inactivation of cytochromes P450 2B4 and 2B4 T302A by tert-butyl acetylenes. Biochemistry 44:3831-3844. (Pubitemid 40358035)
2. Cameron MD, Wen B, Allen KE, Roberts AG, Schuman JT, Campbell AP, Kunze KL, and Nelson SD (2005) Cooperative binding of midazolam with testosterone and alpha-naphthoflavone within the CYP3A4 active site: a NMR T1 paramagnetic relaxation study. Biochemistry 44:14143-14151. (Pubitemid 41533039)
3. Cameron MD, Wen B, Roberts AG, Atkins WM, Campbell AP, and Nelson SD (2007) Cooperative binding of acetaminophen and caffeine within the P450 3A4 active site. Chem Res Toxicol 20:1434-1441. (Pubitemid 350057212)
4. Ciaccio PJ, Duignan DB, and Halpert JR (1987) Selective inactivation by chloramphenicol of the major phenobarbital-inducible isozyme of dog liver cytochrome P-450. Drug Metab Dispos 15:852-856. (Pubitemid 18019780)
5. Cosme J and Johnson EF (2000) Engineering microsomal cytochrome P450 2C5 to be a soluble, monomeric enzyme. Mutations that alter aggregation, phospholipid dependence of catalysis, and membrane binding. J Biol Chem 275:2545-2553. (Pubitemid 30082019)
6. Dalvie DK and O'Connell TN (2004) Characterization of novel dihydrothienopyridinium and thienopyridinium metabolites of ticlopidine in vitro: role of peroxidases, cytochromes P450, and monoamine oxidases. Drug Metab Dispos 32:49-57. (Pubitemid 38112535)
7. de Jonge ME, Huitema AD, Rodenhuis S, and Beijnen JH (2005) Clinical pharmacokinetics of cyclophosphamide. Clin Pharmacokinet 44:1135-1164. (Pubitemid 41483700)
8. Domanski TL and Halpert JR (2001) Analysis of mammalian cytochrome P450 structure and function by site-directed mutagenesis. Curr Drug Metab 2:117-137. (Pubitemid 32536998)
9. Domanski TL, He YQ, Scott EE, Wang Q, and Halpert JR (2001) The role of cytochrome 2B1 substrate recognition site residues 115, 294, 297, 298, and 362 in the oxidation of steroids and 7-alkoxycoumarins. Arch Biochem Biophys 394:21-28.
10. Domanski TL, Schultz KM, Roussel F, Stevens JC, and Halpert JR (1999) Structure-function analysis of human cytochrome P-450 2B6 using a novel substrate, site-directed mutagenesis, and molecular modeling. J Pharmacol Exp Ther 290:1141-1147. (Pubitemid 29400254)
11. Duignan DB, Sipes IG, Leonard TB, and Halpert JR (1987) Purification and characterization of the dog hepatic cytochrome P450 isozyme responsible for the metabolism of 2,2′,4,4′,5,5′-hexachlorobiphenyl. Arch Biochem Biophys 255:290-303.
12. Eyles SJ and Kaltashov IA (2004) Methods to study protein dynamics and folding by mass spectrometry. Methods 34:88-99. (Pubitemid 38993210)
13. Ferguson PL, Kuprowski MC, Boys BL, Wilson DJ, Pan JX, and Konermann L (2009) Protein folding and protein-ligand interactions monitored by electrospray mass spectrometry. Curr Anal Chem 5:186-204.
14. Gay SC, Roberts AG, and Halpert JR (2010a) Structural features of cytochromes P450 and ligands that affect drug metabolism as revealed by x-ray crystallography and NMR. Future Med Chem 2:1451-1468.
15. Gay SC, Roberts AG, Maekawa K, Talakad JC, Hong WX, Zhang Q, Stout CD, and Halpert JR (2010b) Structures of cytochrome P450 2B4 complexed with the antiplatelet drugs ticlopidine and clopidogrel. Biochemistry 49:8709-8720.
16. Gay SC, Shah MB, Talakad JC, Maekawa K, Roberts AG, Wilderman PR, Sun L, Yang JY, Huelga SC, Hong WX, et al. (2010c) Crystal structure of a cytochrome P450 2B6 genetic variant in complex with the inhibitor 4-(4-chlorophenyl) imidazole at 2.0-Å resolution. Mol Pharmacol 77:529-538.
17. Gay SC, Sun L, Maekawa K, Halpert JR, and Stout CD (2009) Crystal structures of cytochrome P450 2B4 in complex with the inhibitor 1-biphenyl-4-methyl-1H-imidazole: ligand induced structural response through α-helical repositioning. Biochemistry 48:4762-4771.
18. Gay SC, Zhang H, Wilderman PR, Roberts AG, Liu T, Li S, Lin HL, Zhang Q, Woods VL, Stout CD, et al. (2011) Structural analysis of mammalian cytochrome P450 2B4 covalently bound to the mechanism-based inactivator tert-butylphenylacetylene: insight into partial enzymatic activity. Biochemistry doi:10.1021/bi100914z.
19. Gotoh O (1992) Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences. J Biol Chem 267:83-90.
20. Ha-Duong NT, Dijols S, Macherey AC, Goldstein JA, Dansette PM, and Mansuy D (2001) Ticlopidine as a selective mechanism-based inhibitor of human cytochrome P450 2C19. Biochemistry 40:12112-12122. (Pubitemid 32946552)
21. Hagihara K, Nishiya Y, Kurihara A, Kazui M, Farid NA, and Ikeda T (2008) Comparison of human cytochrome P450 inhibition by the thienopyridines prasugrel, clopidogrel, and ticlopidine. Drug Metab Pharmacokinet 23:412-420.
22. Halpert J (1981) Covalent modification of lysine during the suicide inactivation of rat liver cytochrome P-450 by chloramphenicol. Biochem Pharmacol 30:875-881.
23. Halpert J, Glaumann H, and Ingelman-Sundberg M (1979) Isolation and incorporation of rabbit liver epoxide hydrase into phospholipid vesicles. J Biol Chem 254:7434-7441.
24. Halpert J, Hammond D, and Neal RA (1980) Inactivation of purified rat liver cytochrome P-450 during the metabolism of parathion (diethyl p-nitrophenyl phosphorothionate). J Biol Chem 255:1080-1089. (Pubitemid 10108151)
25. Halpert J, Jaw JY, Balfour C, and Kaminsky LS (1990) Selective inactivation by chlorofluoroacetamides of the major phenobarbital-inducible form(s) of rat liver cytochrome P-450. Drug Metab Dispos 18:168-174. (Pubitemid 20107710)
26. Halpert J, Näslund B, and Betnér I (1983) Suicide inactivation of rat liver cytochrome P-450 by chloramphenicol in vivo and in vitro. Mol Pharmacol 23:445-452. (Pubitemid 13116870)
27. Halpert J and Neal RA (1980) Inactivation of purified rat liver cytochrome P-450 by chloramphenicol. Mol Pharmacol 17:427-431. (Pubitemid 10117139)
28. Halpert J, Balfour C, Miller NE, Morgan ET, Dunbar D, and Kaminsky LS (1985a) Isozyme selectivity of the inhibition of rat liver cytochromes P-450 by chloramphenicol in vivo. Mol Pharmacol 28:290-296. (Pubitemid 15232551)
29. Halpert JR, Miller NE, and Gorsky LD (1985b) On the mechanism of the inactivation of the major phenobarbital-inducible isozyme of rat liver cytochrome P-450 by chloramphenicol. J Biol Chem 260:8397-8403. (Pubitemid 15249848)
30. He Y, Luo Z, Klekotka PA, Burnett VL, and Halpert JR (1994) Structural determinants of cytochrome P450 2B1 specificity: evidence for five substrate recognition sites. Biochemistry 33:4419-4424. (Pubitemid 24140631)
31. He YA, Balfour CA, Kedzie KM, and Halpert JR (1992) Role of residue 478 as a determinant of the substrate specificity of cytochrome P450 2B1. Biochemistry 31:9220-9226.
32. He YQ, Szklarz GD, and Halpert JR (1996) Interconversion of the androstenedione hydroxylase specificities of cytochromes P450 2B4 and 2B5 upon simultaneous site-directed mutagenesis of four key substrate recognition residues. Arch Biochem Biophys 335:152-160. (Pubitemid 26382690)
33. Hollenberg PF, Kent UM, and Bumpus NN (2008) Mechanism-based inactivation of human cytochromes P450s: experimental characterization, reactive intermediates, and clinical implications. Chem Res Toxicol 21:189-205. (Pubitemid 351219719)
34. Honma W, Li W, Liu H, Scott EE, and Halpert JR (2005) Functional role of residues in the helix B' region of cytochrome P450 2B1. Arch Biochem Biophys 435:157-165. (Pubitemid 40170026)
35. Johnson EF and Stout CD (2005) Structural diversity of human xenobiotic-metabolizing cytochrome P450 monooxygenases. Biochem Biophys Res Commun 338:331-336. (Pubitemid 41540575)
36. Kamataki T and Neal RA (1976) Metabolism of diethyl p-nitrophenyl phosphorothionate (parathion) by a reconstituted mixed-function oxidase enzyme system: studies of the covalent binding of the sulfur atom. Mol Pharmacol 12:933-944.
37. Kedzie KM, Balfour CA, Escobar GY, Grimm SW, He YA, Pepperl DJ, Regan JW, Stevens JC, and Halpert JR (1991) Molecular basis for a functionally unique cytochrome P450IIB1 variant. J Biol Chem 266:22515-22521. (Pubitemid 21908683)
38. Kent UM, Hanna IH, Szklarz GD, Vaz AD, Halpert JR, Bend JR, and Hollenberg PF (1997) Significance of glycine 478 in the metabolism of N-benzyl-1-aminobenzotriazole to reactive intermediates by cytochrome P450 2B1. Biochemistry 36:11707-11716. (Pubitemid 27424095)
39. Kent UM, Mills DE, Rajnarayanan RV, Alworth WL, and Hollenberg PF (2002) Effect of 17-alpha-ethynylestradiol on activities of cytochrome P450 2B (P450 2B) enzymes: characterization of inactivation of P450s 2B1 and 2B6 and identification of metabolites. J Pharmacol Exp Ther 300:549-558.
40. Lin HL, Zhang H, Jushchyshyn M, and Hollenberg PF (2010) Covalent modification of Thr302 in cytochrome P450 2B1 by the mechanism-based inactivator 4-tert-butylphenylacetylene. J Pharmacol Exp Ther 333:663-669.
41. Lin HL, Zhang H, Noon KR, and Hollenberg PF (2009) Mechanism-based inactivation of CYP2B1 and its F-helix mutant by two tert-butyl acetylenic compounds: covalent modification of prosthetic heme versus apoprotein. J Pharmacol Exp Ther 331:392-403.
42. Luo Z, He YA, and Halpert JR (1994) Role of residues 363 and 206 in conversion of cytochrome P450 2B1 from a steroid 16-hydroxylase to a 15α-hydroxylase. Arch Biochem Biophys 309:52-57.
43. Muralidhara BK, Negi S, Chin CC, Braun W, and Halpert JR (2006) Conformational flexibility of mammalian cytochrome P450 2B4 in binding imidazole inhibitors with different ring chemistry and side chains. Solution thermodynamics and molecular modeling. J Biol Chem 281:8051-8061. (Pubitemid 43847423)
44. Ortiz de Montellano PR (1995) The 1994 Bernard B. Brodie Award Lecture. Structure, mechanism, and inhibition of cytochrome P450. Drug Metab Dispos 23:1181-1187.
45. Picard-Fraire C (1984) Pharmacokinetic and metabolic characteristics of ticlopidine in relation to its inhibitory properties on platelet function. Agents Actions Suppl 15:68-75.
46. Poulos TL (2005) Structural and functional diversity in heme monooxygenases. Drug Metab Dispos 33:10-18.
47. Regal KA and Nelson SD (2000) Orientation of caffeine within the active site of human cytochrome P450 1A2 based on NMR longitudinal (T1) relaxation measurements. Arch Biochem Biophys 384:47-58.
48. Richter T, Mürdter TE, Heinkele G, Pleiss J, Tatzel S, Schwab M, Eichelbaum M, and Zanger UM (2004) Potent mechanism-based inhibition of human CYP2B6 by clopidogrel and ticlopidine. J Pharmacol Exp Ther 308:189-197. (Pubitemid 38090717)
49. Roberts ES, Alworth WL, and Hollenberg PF (1998) Mechanism-based inactivation of cytochromes P450 2E1 and 2B1 by 5-phenyl-1-pentyne. Arch Biochem Biophys 354:295-302. (Pubitemid 28373980)
50. Roberts ES, Hopkins NE, Alworth WL, and Hollenberg PF (1993) Mechanism-based inactivation of cytochrome P450 2B1 by 2-ethynylnaphthalene: identification of an active-site peptide. Chem Res Toxicol 6:470-479. (Pubitemid 23212515)
51. Roberts ES, Hopkins NE, Zaluzec EJ, Gage DA, Alworth WL, and Hollenberg PF (1994) Identification of active-site peptides from 3H-labeled 2-ethynylnaphthalene-inactivated P450 2B1 and 2B4 using amino acid sequencing and mass spectrometry. Biochemistry 33:3766-3771. (Pubitemid 24116028)
52. Ruan Q and Zhu M (2010) Investigation of bioactivation of ticlopidine using linear ion trap/orbitrap mass spectrometry and an improved mass defect filtering technique. Chem Res Toxicol 23:909-917.
53. Scott EE, He YA, Wester MR, White MA, Chin CC, Halpert JR, Johnson EF, and Stout CD (2003) An open conformation of mammalian cytochrome P450 2B4 at 1.6-Å resolution. Proc Natl Acad Sci USA 100:13196-13201. (Pubitemid 37444718)
54. Scott EE, Spatzenegger M, and Halpert JR (2001) A truncation of 2B subfamily cytochromes P450 yields increased expression levels, increased solubility, and decreased aggregation while retaining function. Arch Biochem Biophys 395:57-68. (Pubitemid 33030143)
55. Scott EE, White MA, He YA, Johnson EF, Stout CD, and Halpert JR (2004) Structure of mammalian cytochrome P450 2B4 complexed with 4-(4-chlorophenyl) imidazole at 1.9-Å resolution: insight into the range of P450 conformations and the coordination of redox partner binding. J Biol Chem 279:27294-27301. (Pubitemid 38812569)
56. Spatzenegger M, Liu H, Wang Q, Debarber A, Koop DR, and Halpert JR (2003) Analysis of differential substrate selectivities of CYP2B6 and CYP2E1 by site-directed mutagenesis and molecular modeling. J Pharmacol Exp Ther 304:477-487. (Pubitemid 36008960)
57. Spatzenegger M, Wang Q, He YQ, Wester MR, Johnson EF, and Halpert JR (2001) Amino acid residues critical for differential inhibition of CYP2B4, CYP2B5, and CYP2B1 by phenylimidazoles. Mol Pharmacol 59:475-484.
58. Szklarz GD and Halpert JR (1997) Use of homology modeling in conjunction with site-directed mutagenesis for analysis of structure-function relationships of mammalian cytochromes P450. Life Sci 61:2507-2520. (Pubitemid 28035575)
59. Szklarz GD, He YA, and Halpert JR (1995) Site-directed mutagenesis as a tool for molecular modeling of cytochrome P450 2B1. Biochemistry 34:14312-14322.
60. Szklarz GD, He YQ, Kedzie KM, Halpert JR, and Burnett VL (1996) Elucidation of amino acid residues critical for unique activities of rabbit cytochrome P450 2B5 using hybrid enzymes and reciprocal site-directed mutagenesis with rabbit cytochrome P450 2B4. Arch Biochem Biophys 327:308-318. (Pubitemid 26086583)
61. Talakad JC, Shah MB, Walker GS, Xiang C, Halpert JR, and Dalvie D (2011) Comparison of in vitro metabolism of ticlopidine by human cytochrome P450 2B6 and rabbit cytochrome P450 2B4. Drug Metab Dispos 39:539-550.
62. Tuong A, Bouyssou A, Paret J, and Cuong TG (1981) Metabolism of ticlopidine in rats: identification and quantitative determination of some its metabolites in plasma, urine and bile. Eur J Drug Metab Pharmacokinet 6:91-98. (Pubitemid 11032654)
63. Wang H and Tompkins LM (2008) CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme. Curr Drug Metab 9:598-610.
64. Wang Q and Halpert JR (2002) Combined three-dimensional quantitative structure-activity relationship analysis of cytochrome P450 2B6 substrates and protein homology modeling. Drug Metab Dispos 30:86-95. (Pubitemid 34016945)
65. Ward BA, Gorski JC, Jones DR, Hall SD, Flockhart DA, and Desta Z (2003) The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther 306:287-300. (Pubitemid 36734384)
66. Wester MR, Johnson EF, Marques-Soares C, Dansette PM, Mansuy D, and Stout CD (2003a) Structure of a substrate complex of mammalian cytochrome P450 2C5 at 2.3-Å resolution: evidence for multiple substrate binding modes. Biochemistry 42:6370-6379. (Pubitemid 36665811)
67. Wester MR, Johnson EF, Marques-Soares C, Dijols S, Dansette PM, Mansuy D, and Stout CD (2003b) Structure of mammalian cytochrome P450 2C5 complexed with diclofenac at 2.1-Å resolution: evidence for an induced fit model of substrate binding. Biochemistry 42:9335-9345. (Pubitemid 36959241)
68. Wilderman PR, Shah MB, Liu T, Li S, Hsu S, Roberts AG, Goodlett DR, Zhang Q, Woods VLJ, Stout CD, et al. (2010) Plasticity of cytochrome P450 2B4 as investigated by hydrogen-deuterium exchange mass spectrometry and X-ray crystallography. J Biol Chem 285:38602-38611.
69. Williams PA, Cosme J, Sridhar V, Johnson EF, and McRee DE (2000) Mammalian microsomal cytochrome P450 monooxygenase: structural adaptations for membrane binding and functional diversity. Mol Cell 5:121-131. (Pubitemid 30105441)
70. Xie HJ, Yasar U, Lundgren S, Griskevicius L, Terelius Y, Hassan M, and Rane A (2003) Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation. Pharmacogenomics J 3:53-61. (Pubitemid 36432466)
71. Zanger UM, Klein K, Saussele T, Blievernicht J, Hofmann MH, and Schwab M (2007) Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance. Pharmacogenetics 8:743-759. (Pubitemid 47288975)
72. Zhang H, Lin HL, Walker VJ, Hamdane D, and Hollenberg PF (2009) tert-Butylphenylacetylene is a potent mechanism-based inactivator of cytochrome P450 2B4: inhibition of cytochrome P450 catalysis by steric hindrance. Mol Pharmacol 76:1011-1018.
73. Zhao Y, Sun L, Muralidhara BK, Kumar S, White MA, Stout CD, and Halpert JR (2007) Structural and thermodynamic consequences of 1-(4-chlorophenyl) imidazole binding to cytochrome P450 2B4. Biochemistry 46:11559-11567. (Pubitemid 47585501)
74. Zhao Y, White MA, Muralidhara BK, Sun L, Halpert JR, and Stout CD (2006) Structure of microsomal cytochrome P450 2B4 complexed with the antifungal drug bifonazole: insight into P450 conformational plasticity and membrane interaction. J Biol Chem 281:5973-5981. (Pubitemid 43847698)